- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
R&D increases Neoprobe's red ink
Gamma-ray probe manufacturerNeoprobe said this month that it expects to post a loss of $8million for 1993 (end-December), compared to $2.6 million for1992. The loss is due to increased spending in four clinical trialsNeoprobe is conducting to support a
Gamma-ray probe manufacturerNeoprobe said this month that it expects to post a loss of $8million for 1993 (end-December), compared to $2.6 million for1992. The loss is due to increased spending in four clinical trialsNeoprobe is conducting to support a filing with the Food and DrugAdministration for clearance to market its monoclonal antibody-basedproducts.
Neoprobe reported operating expenses for the year of $8.3 million,which includes $5.9 million for research and development. TheColumbus, OH-based company spent $4.1 million on clinical trialsfor its radioimmunoguided surgery (RIGS) technology for detectionof colorectal, breast and ovarian cancer, as well as on trialsfor an adoptive cellular therapy (RIGS/ACT) product. Neoprobeearned $325,000 in interest income for the year.
RIGS technology involves injecting cancer patients with radiolabeledmonoclonal antibodies and using a hand-held probe during surgeryto detect concentrations of malignant tissue. Neoprobe has acquiredrights to Dow Chemical's CC49 antibody for its RIGScan CR49 product,which is used for surgical detection of colorectal cancer (SCAN8/11/93 and 2/24/93).
The company is sponsoring two phase-three clinical trials forRIGScan CR49, it said. Neoprobe is sponsoring separate phase-twostudies for RIGS detection of ovarian and breast cancer.
Neoprobe also signed an exclusive agent licensing arrangementlast week with the Institut Armand-Frappier at the Universityof Quebec. The licensed monoclonal antibody agent, BCD-F9, hasbeen used by researchers investigating RIGS technology. It mayhave use for topical and intraoperative scanning of breast cancerpatients to localize tumors in the lymph notes, the company said.
In other news, the probe firm named J. Kenneth Poggenburg asvice president of operations. Poggenburg comes to Neoprobe frommonoclonal antibody agent developer Hybritech, where he was directorof R&D. Hybritech's parent Eli Lilly said earlier this yearthat it plans to sell the biotechnology subsidiary (SCAN 2/2/94).
Study Reaffirms Low Risk for csPCa with Biopsy Omission After Negative Prostate MRI
December 19th 2024In a new study involving nearly 600 biopsy-naïve men, researchers found that only 4 percent of those with negative prostate MRI had clinically significant prostate cancer after three years of active monitoring.
Study Examines Impact of Deep Learning on Fast MRI Protocols for Knee Pain
December 17th 2024Ten-minute and five-minute knee MRI exams with compressed sequences facilitated by deep learning offered nearly equivalent sensitivity and specificity as an 18-minute conventional MRI knee exam, according to research presented recently at the RSNA conference.
Can Radiomics Bolster Low-Dose CT Prognostic Assessment for High-Risk Lung Adenocarcinoma?
December 16th 2024A CT-based radiomic model offered over 10 percent higher specificity and positive predictive value for high-risk lung adenocarcinoma in comparison to a radiographic model, according to external validation testing in a recent study.
